



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	328492	Lactoferrin Enhanced
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Natural Bio Pty Limited	
<b>Postal Address</b>	PO Box 384, MONA VALE, NSW, 1660 Australia	
<b>ARTG Start Date</b>	13/01/2020	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Lactoferrin Enhanced

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	5/03/2020
---------------------	-------------------------	-----------------------	-----------

#### Permitted Indications

Maintain/support bone health  
Maintain/support immune system health  
Relieve symptoms of acne

#### Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to serious immunological diseases.

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).

Contains milk/milk products.

If symptoms persist consult your healthcare practitioner (or words to that effect).

#### Additional Product information

#### Pack Size/Poison information

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

Pack Size

Poison Schedule

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Bifidobacterium lactis</b>	<b>5 billion CFU</b>
<b>bovine lactoferrin</b>	<b>100 mg</b>
<b>d-alpha-tocopheryl acid succinate</b>	<b>9.09 mg</b>
<b>Olea europaea</b>	<b>125 mg</b>
<b>zinc glycinate</b>	<b>47.021 mg</b>
Equivalent: zinc	15 mg

**Other Ingredients (Excipients)**

carrageenan

citric acid

colloidal anhydrous silica

hypromellose

magnesium stearate

microcrystalline cellulose

potassium acetate

purified water

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary